17R Stock Chart & Stats
€33.00
€0.00(0.00%)
At close: 4:00 PM EDT
€33.00
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€13.40 - €36.20
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€4.51B
Enterprise Value€2.79K
Total Cash (Recent Filing)€264.68M
Total Debt (Recent Filing)€327.66M
Price to Earnings (P/E)―
Beta1.08
Next Earnings
Aug 04, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding92,992,905
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.79
Price to Book (P/B)29.69
Price to Sales (P/S)6.95
P/FCF Ratio-167.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€51.73Price Target Upside56.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-0.03
Revenue Forecast (FY)€593.86M
Bulls Say, Bears Say
Bulls Say
Regulatory Milestone: FSGS ApprovalBeing the first and only FDA‑approved therapy for FSGS materially expands Travere's durable addressable market and clinical positioning. The approval opens >30,000 U.S. FSGS patients (and >100,000 total across IgA/FSGS), strengthening payer negotiations and long‑term uptake dynamics.
Strong Commercial Traction & Payer AccessSustained high prescription starts, steep YoY growth and established payer access (~97%) indicate robust commercial execution. These durable commercial capabilities support predictable revenue scaling, reduce launch friction for new indications, and improve the odds of converting eligible patients into long‑term users.
Pipeline Expansion Via Civorebrutinib LicenseThe exclusive license broadens Travere's kidney‑disease R&D footprint with a novel BTK asset, diversifying future revenue levers and indication coverage. This structural deal adds late‑stage development optionality and a strategic 10‑year non‑compete, supporting long‑term franchise building despite added obligations.
Bears Say
Elevated LeverageHigh debt relative to equity constrains financial flexibility and increases refinancing and interest risk over time. Even after recent refinancings, leverage limits capacity for opportunistic M&A, higher R&D spend without dilutive financing, and makes operating cash flow consistency critical for balance‑sheet stability.
Ongoing GAAP Losses And Rising Operating CostsMaterial increases in R&D and SG&A to support launches and trials raise the break‑even threshold. Continued GAAP losses mean profitability depends on sustained FILSPARI growth and successful pipeline outcomes; if revenue growth slows, elevated fixed costs could pressure margins and cash generation.
Pipeline Execution And Competitive RiskKey pipeline readouts (eg, HARMONY in 2027) and commercialization of new indications carry execution and regulatory risk. Simultaneous entrants in IgA nephropathy and uncertainties around clinical timelines could limit peak penetration and extend the time required to realize modeled revenues.
Travere Therapeutics News
17R FAQ
What was Travere Therapeutics’s price range in the past 12 months?
Travere Therapeutics lowest stock price was €13.40 and its highest was €36.20 in the past 12 months.
What is Travere Therapeutics’s market cap?
Travere Therapeutics’s market cap is €4.51B.
When is Travere Therapeutics’s upcoming earnings report date?
Travere Therapeutics’s upcoming earnings report date is Aug 04, 2026 which is today.
How were Travere Therapeutics’s earnings last quarter?
Currently, no data Available
Is Travere Therapeutics overvalued?
According to Wall Street analysts Travere Therapeutics’s price is currently Undervalued.
Does Travere Therapeutics pay dividends?
Travere Therapeutics does not currently pay dividends.
What is Travere Therapeutics’s EPS estimate?
Travere Therapeutics’s EPS estimate is -0.12.
How many shares outstanding does Travere Therapeutics have?
Travere Therapeutics has 92,992,905 shares outstanding.
What happened to Travere Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Travere Therapeutics?
Currently, no hedge funds are holding shares in DE:17R
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Travere Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€51.73 (56.76% Upside)
€51.73 (56.76% Upside)
Blogger Sentiment
Bullish
DE:17R Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
259.62%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1.16%
Trailing 12-Months
Company Description
Travere Therapeutics
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
17R Company Deck
17R Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strongly positive commercial and clinical momentum: a landmark FDA approval in FSGS, record demand and an 88% YoY increase in FILSPARI sales, encouraging pipeline progress (HARMONY restart with 2027 readout expectation), and improved non-GAAP profitability. Offsetting these positives are significant near-term cost increases (R&D and SG&A), higher royalty expense due to accounting changes, a continuing GAAP net loss, and some short-term revenue recognition/timing headwinds and education needs with physicians and payers. Overall, the positives (major approval, large sales growth, record demand, and clear runway to advance the pipeline) outweigh the near-term financial and operational challenges.View all DE:17R earnings summaries17R Stock 12 Month Forecast
Average Price Target
€51.73
▲(56.76% Upside)
Technical Analysis
―
Arcutis Biotherapeutics
―
Disc Medicine
―
Tarsus Pharmaceuticals
―
Recursion Pharmaceuticals
―